Source comparison
Is CJC-1295 Safe Long Term Use: Drug Comparison
Half-Life 6–8 days 30 minutes 4–6 hours 2–3 hours CJC-1295's extended half-life reduces injection frequency but increases cumulative exposure. No approved GH therapy uses this pharmacokinetic profile Mechanism GHRH receptor agonist Ghrelin mimetic Direct GH re
This comparison does not assign a generated winner or score.
- Half-Life
- 6–8 days
- 30 minutes
- 4–6 hours
- 2–3 hours
- CJC-1295's extended half-life reduces injection frequency but increases cumulative exposure. No approved GH therapy uses this pharmacokinetic profile
- Mechanism
- GHRH receptor agonist
- Ghrelin mimetic
- Direct GH replacement
- CJC-1295 preserves pulsatile GH release; exogenous GH suppresses endogenous production entirely
- Longest Published Human Trial
- 90 days
- 28 days
- 2 years (elderly sarcopenia study)
- Decades (paediatric/adult GH deficiency)
- MK-677 has the only long-term oral secretagogue data; CJC-1295 evidence stops at 13 weeks
- IGF-1 Elevation
- 1.5–2.5× baseline
- 1.2–1.8× baseline
- 1.3–1.9× baseline
- Dose-dependent, often >3× in replacement therapy
- All raise IGF-1, but CJC-1295 sustains elevation between doses due to DAC binding
- Documented Long-Term Risks
- None (no data >90 days)
- None (no data >28 days)
- Mild insulin resistance, increased appetite
- Acromegaly-like features at supraphysiological doses
- Absence of long-term CJC-1295 data is the critical gap. We extrapolate from GH physiology, not direct evidence
- Regulatory Status
- Research compound only
- FDA-approved (prescription-only)
- Only exogenous GH has undergone rigorous long-term safety monitoring in clinical use
- The comparison underscores the evidence problem: CJC-1295 sits in a category with no approved therapeutic analogue. Its pharmacokinetics are unique, its long-term human data is absent, and safety extrapolations rely on assumptions rather than trials.